School of Life Science and Technology, Tongji University, 1239 SiPing Road, Shanghai 200092, PR China.
Comput Biol Chem. 2011 Jun;35(3):189-92. doi: 10.1016/j.compbiolchem.2011.04.010. Epub 2011 May 5.
Glucose-6-phosphate dehydrogenase (G6PD) is an essential enzyme that protects human red blood cells from premature destruction caused by oxidative damage. People suffering from G6PD deficiency would be vulnerable to various oxidative substances, such as fava beans and oxidant drugs. Until now, many institutes, organizations or domain experts have compiled low-risk or high-risk drugs collection for patients with G6PD deficiency, mainly from the case report or clinical trails. Recently, we have explored a classification system to predict drug-induced hemolytic potential. In this paper, we screen the normally used over-the-counter (OTC) drugs for "high-risk" and "low-risk" ones to G6PD deficient patients by this system.
葡萄糖-6-磷酸脱氢酶（G6PD）是一种重要的酶，可保护人类红细胞免受氧化损伤引起的过早破坏。患有 G6PD 缺乏症的人容易受到各种氧化物质的影响，如蚕豆和氧化剂药物。到目前为止，许多研究所、组织或领域专家已经为 G6PD 缺乏症患者编制了低风险或高风险药物的集合，主要是基于病例报告或临床试验。最近，我们探索了一种分类系统来预测药物诱导的溶血性潜力。在本文中，我们通过该系统筛选出“高风险”和“低风险”的常用非处方（OTC）药物。
